3152 related articles for article (PubMed ID: 7705956)
1. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.
Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN
Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.
Takayama T; Tahara H; Thomson AW
Transplantation; 2001 May; 71(9):1334-40. PubMed ID: 11397973
[TBL] [Abstract][Full Text] [Related]
3. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
4. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
5. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
6. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.
Zier KS; Gansbacher B
Eur J Cancer; 1996 Jul; 32A(8):1408-12. PubMed ID: 8869107
[TBL] [Abstract][Full Text] [Related]
7. A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection.
Denkers EY; Scharton-Kersten T; Barbieri S; Caspar P; Sher A
J Exp Med; 1996 Jul; 184(1):131-9. PubMed ID: 8691126
[TBL] [Abstract][Full Text] [Related]
8. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
Hock H; Dorsch M; Kunzendorf U; Qin Z; Diamantstein T; Blankenstein T
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2774-8. PubMed ID: 8464888
[TBL] [Abstract][Full Text] [Related]
10. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
11. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.
Ewend MG; Thompson RC; Anderson R; Sills AK; Staveley-O'Carroll K; Tyler BM; Hanes J; Brat D; Thomas M; Jaffee EM; Pardoll DM; Brem H
J Immunother; 2000; 23(4):438-48. PubMed ID: 10916753
[TBL] [Abstract][Full Text] [Related]
12. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
[TBL] [Abstract][Full Text] [Related]
13. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement.
Di Carlo E; Comes A; Basso S; De Ambrosis A; Meazza R; Musiani P; Moelling K; Albini A; Ferrini S
J Immunol; 2000 Sep; 165(6):3111-8. PubMed ID: 10975824
[TBL] [Abstract][Full Text] [Related]
14. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
[TBL] [Abstract][Full Text] [Related]
15. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma.
Knisely TL; Niederkorn JY
Invest Ophthalmol Vis Sci; 1990 Feb; 31(2):247-57. PubMed ID: 2154414
[TBL] [Abstract][Full Text] [Related]
16. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
17. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
Levitsky HI; Lazenby A; Hayashi RJ; Pardoll DM
J Exp Med; 1994 Apr; 179(4):1215-24. PubMed ID: 7908321
[TBL] [Abstract][Full Text] [Related]
18. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
McMenamin C; Holt PG
J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
[TBL] [Abstract][Full Text] [Related]
19. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells.
Kim TS; Cohen EP
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):24-35. PubMed ID: 8081557
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
Ouyang GF; Saio M; Suwa T; Imai H; Nakagawa J; Nonaka K; Umemura N; Kijima M; Takami T
Int J Oncol; 2006 May; 28(5):1201-8. PubMed ID: 16596236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
